# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# FORM 6-K

### REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

December 2022

Commission File Number: 001-41386

# **OKYO Pharma LTD**

(Exact Name of Registrant as Specified in Its Charter)

9<sup>th</sup> Floor 107 Cheapside London EC2V 6DN

(Address of registrant's principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.		
Form 20-F ⊠ Form 40-F □		
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): □		
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): □		

#### INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On December 22, 2022, OKYO Pharma LTD (the "Company") issued this 6K announcing the U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibit 99.1 is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

## **OKYO Pharma LTD**

Date: December 22, 2022 By: \(\frac{s}{\text{ Gary Jacob}}\)

Name:Gary Jacob

Title: Chief Executive Officer

3

# **EXHIBIT INDEX**

Exhibit No.		Description
99.1	News Announcement, dated December 22, 2022	
	4	